The $10m will be used to develop Regentis's European presence and expand its ongoing clinical efforts of GelrinC, a biodegradable implant that enhances growth of articular cartilage in damaged knee joints.
Regentis Biomaterials, a US and Israel-based developer of hydrogels for human tissue regeneration, has raised $10m in its series C round from a consortium including Netherlands-based industrial group Royal DSM.
The $10m will be used to develop Regentis’s European presence and expand its ongoing clinical efforts of GelrinC, a biodegradable implant that enhances growth of articular cartilage in damaged knee joints.
Also in the syndicate are venture capital firms Crossroad Fund, Medica Venture Partners, SCP-Vitalife and the Technion Investment Opportunities…
